In the BioHarmony Drug Report Database
Navstel (oxiglutatione) is a small molecule pharmaceutical. Oxiglutatione was first approved as Navstel on 2008-07-24. The pharmaceutical is active against glutathione reductase, mitochondrial. In addition, it is known to target glutathione S-transferase Mu 2. Navstel’s patent is valid until 2021-11-29 (FDA).
Image (chem structure or protein)